School of Biological Sciences and Institute of Microbiology, Seoul National University, Seoul, 08826, Republic of Korea.
J Microbiol. 2022 Jun;60(6):561-575. doi: 10.1007/s12275-022-2087-y. Epub 2022 May 5.
Growing evidence suggests that the gut microbiome is an important contributor to metabolic diseases. Alterations in microbial communities are associated with changes in lipid metabolism, glucose homeostasis, intestinal barrier functions, and chronic inflammation, all of which can lead to metabolic disorders. Therefore, the gut microbiome may represent a novel therapeutic target for obesity, type 2 diabetes, and nonalcoholic fatty liver disease. This review discusses how gut microbes and their products affect metabolic diseases and outlines potential treatment approaches via manipulation of the gut microbiome. Increasing our understanding of the interactions between the gut microbiome and host metabolism may help restore the healthy symbiotic relationship between them.
越来越多的证据表明，肠道微生物组是代谢疾病的一个重要贡献者。微生物群落的改变与脂质代谢、葡萄糖稳态、肠道屏障功能和慢性炎症的变化有关，所有这些都可能导致代谢紊乱。因此，肠道微生物组可能代表肥胖、2 型糖尿病和非酒精性脂肪肝疾病的一个新的治疗靶点。这篇综述讨论了肠道微生物及其产物如何影响代谢疾病，并概述了通过操纵肠道微生物组来进行潜在治疗的方法。增加我们对肠道微生物组和宿主代谢之间相互作用的理解，可能有助于恢复它们之间的健康共生关系。
